

In the Claims

Please cancel claims 10-13, 16-36, and 38, without prejudice.

Please substitute the following claims:

Claim 1 (twice amended):

AP1 SUB 1
1. A method for the treatment or prevention of intimal hyperplasia of a blood vessel of a person or animal, where the endothelium of said blood vessel is intact, wherein said method comprises periadventitial administration to said blood vessel of said person or animal of an amount of an agent that is effective to treat or prevent intimal hyperplasia of said blood vessel, wherein said agent comprises a nucleic acid that encodes an agonist of a receptor to which VEGF binds and expressing said agonist encoded by said nucleic acid in the cells of said blood vessel.

Claim 7 (twice amended):

12
7. The method according to claim 1, wherein said nucleic acid encodes a human VEGF protein.

Claim 8 (twice amended):

12
8. The method according to claim 7, wherein said protein has the sequence of SEQ. ID No. 2, SEQ. ID No. 4, SEQ. ID No. 6 or SEQ. ID No. 8, or a biologically-active fragment thereof.

Claim 9 (twice amended):

9. The method according to claim 1, wherein said nucleic acid is in association with a viral or non-viral vector.

Claim 14 (amended):

13
14. A method of therapy for a condition that can be treated or prevented by stimulation of one or both of nitric oxide (NO) and prostacyclin production *in vivo*, wherein said method comprises administration to a person or animal of an amount of an agent that is effective for therapeutic treatment of said condition, wherein said agent comprises a nucleic acid that encodes an agonist of a receptor to which VEGF binds and expressing said agonist encoded by said nucleic acid.